Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients.

about

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients.

Item

http://www.wikidata.org/entity/Q54978822

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Differential proteomic profile ...... nic myeloid leukemia patients.

@en

Differential proteomic profile ...... nic myeloid leukemia patients.

@nl

type

Item

label

Differential proteomic profile ...... nic myeloid leukemia patients.

@en

Differential proteomic profile ...... nic myeloid leukemia patients.

@nl

prefLabel

Differential proteomic profile ...... nic myeloid leukemia patients.

@en

Differential proteomic profile ...... nic myeloid leukemia patients.

@nl

P1476

Differential proteomic profile ...... nic myeloid leukemia patients.

@en

P2093

Agostino Tafuri

http://www.w3.org/2001/XMLSchema#string

Maria Rosaria Ricciardi

http://www.w3.org/2001/XMLSchema#string

Roberto Licchetta

http://www.w3.org/2001/XMLSchema#string

Roberto Massimo Lemoli

http://www.w3.org/2001/XMLSchema#string

Rossella Manfredini

http://www.w3.org/2001/XMLSchema#string

Silvio Bicciato

http://www.w3.org/2001/XMLSchema#string

Simona Salati

http://www.w3.org/2001/XMLSchema#string

Simone Mirabilii

http://www.w3.org/2001/XMLSchema#string

Valentina Salvestrini

http://www.w3.org/2001/XMLSchema#string

P2860

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

Global proteome quantification for discovering imatinib-induced perturbation of multiple biological pathways in K562 human chronic myeloid leukemia cells

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.

BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia

Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.

Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells

P304

21758-21769

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24938

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29774100

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

chronic myeloid leukemia

P932

5955129

http://www.w3.org/2001/XMLSchema#string